All products are sold strictly for laboratory research use only. Not for human or veterinary consumption, diagnosis, or treatment. Not approved by the FDA.

Research Use Only

Search results for "LC-MS"

Found 9 products

9 results

Sort by:

Tirzepatide (15mg)

Tirzepatide (15mg)

Tirzepatide (LY3298176) is a first-in-class 39-amino acid dual GIP/GLP-1 receptor agonist ("twincretin") with imbalanced agonism favoring GIPR over GLP-1R
Features Aib residues at positions 2 and 13 (DPP-4 resistance), C20 fatty diacid at Lys20 (albumin binding, ~5-day half-life), and biased GLP-1R signaling favoring cAMP over beta-arrestin recruitment
FDA-approved as Mounjaro (T2D, May 2022) and Zepbound (obesity, Nov 2023)

$129.00

Retatrutide (20mg)

Retatrutide (20mg)

Retatrutide (LY3437943) is a first-in-class 39-amino acid triple agonist of GIPR, GLP-1R, and GCGR
Research demonstrates up to 24
2% mean body weight reduction in Phase 2 obesity trials, superior to single and dual agonists

$199.00

Retatrutide (40mg)

Retatrutide (40mg)

Retatrutide (LY3437943) is a first-in-class 39-amino acid triple agonist of GIPR, GLP-1R, and GCGR
Research demonstrates up to 24
2% mean body weight reduction in Phase 2 obesity trials, superior to single and dual agonists

$329.00

Retatrutide (5mg)

Retatrutide (5mg)

Retatrutide (LY3437943) is a first-in-class 39-amino acid triple agonist of GIPR, GLP-1R, and GCGR
Research demonstrates up to 24
2% mean body weight reduction in Phase 2 obesity trials, superior to single and dual agonists

$69.00

Cagrilintide (5mg) / Tirz (10mg)

Cagrilintide (5mg) / Tirz (10mg)

Triple-Receptor Agonist: Combines amylin, GIP, and GLP-1 pathways in one formulation
Multi-Pathway Engagement: Three independent satiety and metabolic control mechanisms
Research Blend: 5mg Cagrilintide + 10mg Tirzepatide, ≥98% purity each component

$199.00

$149.00

Semaglutide Capsules (500mcg) 25 Count

Semaglutide Capsules (500mcg) 25 Count

Oral semaglutide is a 31-amino acid GLP-1 receptor agonist with engineered modifications (Aib8, C-18 fatty di-acid, Lys34Arg) enabling oral bioavailability via SNAC absorption enhancement technology
Research demonstrates glycemic control comparable to injectable GLP-1 agonists with 15
1% weight loss (50mg dose, OASIS-1 trial)

$99.00

AOD9604 6mg

AOD9604 6mg

Synthetic hGH Fragment: 16-amino acid C-terminal peptide (177-191), ≥98% purity
Beta-3-AR Upregulation: Enhances lipolysis while suppressing lipogenesis without IGF-1 elevation
Metabolic Research: Six human trials (900+ participants), FDA GRAS status

$48.00

5-Amino-1MQ 50mg (60 Capsules)

5-Amino-1MQ 50mg (60 Capsules)

NNMT Inhibitor: Small-molecule inhibitor of nicotinamide N-methyltransferase (IC50 = 1.2 μM), ≥98% purity
NAD+ Salvage Enhancement: Preserves nicotinamide for NAD+ biosynthesis; elevates intracellular NAD+ by 1.2-1.6-fold
Metabolic Research: Studied in obesity, muscle aging, cardiovascular function, and neurodegenerative disease models

$99.00

BAM15 (15mg) 60 capsules

BAM15 (15mg) 60 capsules

Mitochondrial Uncoupler: Selective protonophore (C₁₆H₁₀F₂N₆O), ≥98% purity
AMPK Activation: 1,000-fold greater potency than metformin per unit concentration
Metabolic Research: 50+ publications since 2014, validated in Nature Communications

$99.00